Insider Selling: Henry Schein (NASDAQ:HSIC) EVP Sells $478,740.00 in Stock

Henry Schein, Inc. (NASDAQ:HSIC) EVP Mark Mlotek sold 5,925 shares of the stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $80.80, for a total value of $478,740.00. Following the completion of the transaction, the executive vice president directly owned 80,554 shares of the company’s stock, valued at $6,508,763.20. This represents a 6.85% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Henry Schein Price Performance

HSIC stock opened at $77.60 on Monday. The company has a quick ratio of 0.76, a current ratio of 1.38 and a debt-to-equity ratio of 0.59. Henry Schein, Inc. has a 52-week low of $60.56 and a 52-week high of $89.29. The stock’s 50 day moving average is $78.20 and its two-hundred day moving average is $72.63. The company has a market capitalization of $8.90 billion, a PE ratio of 23.73, a P/E/G ratio of 2.30 and a beta of 0.87.

Henry Schein (NASDAQ:HSIC) last announced its earnings results on Tuesday, February 24th. The company reported $1.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.30 by $0.04. The company had revenue of $3.44 billion for the quarter, compared to analyst estimates of $3.34 billion. Henry Schein had a return on equity of 15.16% and a net margin of 3.02%.Henry Schein’s quarterly revenue was up 7.7% on a year-over-year basis. During the same period in the prior year, the company posted $1.19 EPS. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Analysts predict that Henry Schein, Inc. will post 4.74 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. Leerink Partners increased their price objective on shares of Henry Schein from $75.00 to $87.00 and gave the company a “market perform” rating in a research note on Tuesday, February 24th. Wells Fargo & Company boosted their target price on shares of Henry Schein from $76.00 to $87.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 25th. Morgan Stanley upped their target price on shares of Henry Schein from $58.00 to $61.00 and gave the company an “underweight” rating in a research note on Wednesday, February 25th. Robert W. Baird set a $100.00 price target on shares of Henry Schein and gave the stock an “outperform” rating in a research report on Monday, February 23rd. Finally, JPMorgan Chase & Co. lifted their price target on Henry Schein from $78.00 to $92.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. Six investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $85.58.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Ameriprise Financial Inc. increased its holdings in shares of Henry Schein by 3,275.2% during the second quarter. Ameriprise Financial Inc. now owns 2,266,858 shares of the company’s stock valued at $165,594,000 after purchasing an additional 2,199,695 shares during the period. Bank of Montreal Can grew its position in Henry Schein by 3,655.7% in the 4th quarter. Bank of Montreal Can now owns 2,144,773 shares of the company’s stock valued at $162,102,000 after buying an additional 2,087,666 shares in the last quarter. Norges Bank acquired a new position in Henry Schein during the 2nd quarter valued at about $89,476,000. M.D. Sass LLC bought a new stake in shares of Henry Schein during the 2nd quarter worth about $79,201,000. Finally, Schroder Investment Management Group lifted its stake in shares of Henry Schein by 149.3% in the 2nd quarter. Schroder Investment Management Group now owns 1,563,899 shares of the company’s stock worth $114,243,000 after acquiring an additional 936,471 shares during the period. Institutional investors and hedge funds own 96.62% of the company’s stock.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.